Eli Lilly CEO Dave Ricks said in a CNBC interview published September 21, 2026 that roughly 700,000 seniors have started GLP-1 obesity medications since Medicare's new coverage program began, and that Lilly's drugs account for about 70% of those new patients, a figure the company says is even higher than its roughly 60% share of the broader U.S. obesity-drug market.
What the Medicare Bridge Program Is
The Medicare GLP-1 Bridge demonstration program, which this site covered at launch, took effect July 1, 2026 as part of a set of "most favored nation" style drug-pricing arrangements. It lets eligible seniors access GLP-1 obesity medications for a $50 monthly copay, with Medicare paying a negotiated net price reported at roughly $245 per month. Enrollment has climbed steadily since launch: reported at 500,000 patients in late August, 600,000 by August 31, and 700,000 by September 23.
Lilly's Market Position
Ricks said Lilly's tirzepatide-based drugs, sold as Zepbound for weight loss and Mounjaro for type 2 diabetes, are capturing about 70% of the new Medicare-covered population. He also said Lilly's oral GLP-1 pill, Foundayo (orforglipron), now accounts for roughly one in three new patients starting an oral GLP-1 for obesity in the U.S. market, despite launching several months after Novo Nordisk's competing oral semaglutide pill. Independent analysts covering the announcement estimated the Medicare bridge program alone could translate to roughly $1.4 billion in annualized revenue for Lilly at the current 70% share, with one analyst modeling a potential $3 billion to $3.5 billion annualized run rate by year-end if enrollment keeps growing.
Why This Matters Beyond One Company's Earnings
This isn't just a competitive win for one company. The Medicare enrollment numbers are one of the clearest real-world signals yet of how quickly government-subsidized access changes prescribing patterns once a major reimbursement barrier is removed. It's also a data point in the broader Lilly-versus-Novo competition this site has tracked, including Lilly's earlier earnings lead over Novo's oral pill and Novo's own strategic pivot toward its next generation of obesity drugs.
What Isn't Being Announced Here
It's worth being precise about what this story is and isn't. There's no new FDA approval, no new clinical trial data, and no change to either drug's regulatory or safety status attached to these figures. This is business and enrollment reporting, disclosed by a company executive in a media interview rather than in a formal regulatory filing or peer-reviewed source, and the projected revenue figures cited above are analyst estimates rather than guidance issued by Lilly itself.
The Bottom Line
Tirzepatide (Zepbound/Mounjaro) and orforglipron (Foundayo) remain the same FDA-approved medications with the same prescribing information and side-effect profiles as before this announcement; what's changed is the number of Medicare patients now able to access them at a subsidized price, and which company is winning the race to prescribe them. Anyone considering a GLP-1 medication through the Medicare bridge program should talk to their doctor about eligibility, since the program has its own criteria separate from a drug's general FDA-approved indication.